GNQ Insilico Secures MindLab, an Award Winning Pharma Company, as a Client for its Drug Assessment Platform
GNQ Insilico’s Quantum-enhanced and AI-powered Platform to Accelerate Development of MindLab’s Novel Pain Management Therapy PLEASANTON, CA, UNITED STATES, October 30, 2025 /EINPresswire.com/ — GNQ Insilico Inc., a pioneer in quantum-enhanced AI drug development, is pleased to announce a strategic partnership with MindLab, LLC to deploy its newly launched Drug Assessment Platform (DAP) to accelerate […]
GNQ Insilico Launches Revolutionary AI-Driven Assessment Platform to Transform Precision Medicine and Drug Development
Multi-Agentic AI Platform Powered by Proprietary Systems Biology Engine Delivers Personalized Therapy Optimization and Investment Risk Assessment PLEASANTON, CA, UNITED STATES, September 10, 2025 /EINPresswire.com/ — GNQ Insilico Inc. (“GNQ” or “the Company”), a pioneering TechBio firm leveraging exponential technologies for precision medicine, announces the official launch of its groundbreaking deep tech Drug Assessment Platform […]
GNQ Insilico Unveils Multi-Pathway Therapeutic Formulation for ALS Leveraging proprietary Drug Assessment Platform
GNQ Insilico, Inc. (“GNQ” or “the Company”), a cutting-edge TechBio platform company, announced results from its proprietary Drug Assessment Platform. GNQ’s platform represents a breakthrough in computational drug development and due diligence, providing investors and pharmaceutical partners with unprecedented insights into multi-pathway therapeutic optimization. To demonstrate the platform’s transformative capabilities, GNQ has developed a novel, […]
GNQ’s Drug Assessment Platform Enhances Non-Small Cell Lung Cancer Treatment by Extending Efficacy Beyond Universal Resistance Barrier
GNQ Insilico, Inc. (“GNQ” or “the Company”), a TechBio platform company, demonstrated the advanced capabilities of its AI-powered Drug Assessment Platform in addressing critical treatment optimization challenges for patients with Non-Small Cell Lung Cancer (NSCLC). NSCLC remains the leading cause of cancer-related mortality, representing 85% of all lung cancer cases[1]. Patients face significant treatment challenges […]
GNQ presents at Quantum Rising Conference alongside Deloitte & IBM Quantum
Sudhir Saxena, Chief Technology Officer of GNQ Insilico, Inc. (GNQ), was invited by Deloitte Consulting to present GNQ’s multi-omics approach to personalized medicine through AI-powered digital twins at the Quantum Rising Conference held on December 14 and 15 in Atlanta, Georgia (hosted by the National Quantum Literacy Network). At the Quantum Rising conference, Saxena was […]
GNQ Insilico’s AI-Driven Digital Twins Platform Shows Promising Results in Simulating Effects of a Drug on Synthesized Digital Twins
GNQ Insilico’s AI-Driven Digital Twins Platform Shows Promising Results in Simulating Effects of a Drug on Synthesized Digital Twins June 18, 2024 GNQ Insilico, Inc. (“GNQ” or “the Company”), a cutting-edge TechBio platform company, demonstrated promising results in synthesizing digital twins human patients, and simulating the effects of an infertility drug on these digital replicas […]
GNQ Unveils AI-Powered Platform Prototype Delivering 128% AUC Improvement in Personalized Clomiphene Dosing Optimization
GNQ Insilico, Inc. (“GNQ” or “the Company”), a TechBio platform company, announced the successful development and validation of its AI-powered Drug Assessment Platform prototype for clomiphene citrate dose optimization. The fertility treatment market represents a significant opportunity, with clomiphene citrate being a first-line therapy for ovulatory dysfunction affecting millions of women globally. This proof-of-concept demonstrates […]
GNQ Insilico Announces Collaboration with Fortune 100 Company to Develop Next-Generation Clinical Trial Platform
SAN FRANCISCO, CALIFORNIA, USA, March 4, 2024 /EINPresswire.com/ — GNQ Insilico Inc. (“GNQ”), a company developing a generative artificial intelligence and quantum computing platform to assist life sciences companies in conducting in silico clinical trials for drug discovery and drug development, is pleased to announce that it has commenced the development of the platform with […]
